- Histologically documented, advanced or recurrent squamous cell carcinoma of uterine
cervix. Patients may have received concurrent (with radiotherapy) or (neo)adjuvant
(before or after local treatment) chemotherapy for primary tumor providing that at
least 6 months have passed from the completion of previous therapy and the diagnosis
of recurrent disease was documented
- Having measurable lesion(s), without previous radiation therapy.
- Patients had ever received primary chemotherapy for cervical cancer other than
mentioned previously (in the inclusion criteria).
- Patients ever received cisplatin with total dose > 300 mg/m2 and received radiotherapy
or local treatment delivered to the target lesion.